CN105601736A - 一种抗呼吸道合胞病毒人免疫球蛋白及其制备方法 - Google Patents
一种抗呼吸道合胞病毒人免疫球蛋白及其制备方法 Download PDFInfo
- Publication number
- CN105601736A CN105601736A CN201610060348.9A CN201610060348A CN105601736A CN 105601736 A CN105601736 A CN 105601736A CN 201610060348 A CN201610060348 A CN 201610060348A CN 105601736 A CN105601736 A CN 105601736A
- Authority
- CN
- China
- Prior art keywords
- liquid
- respiratory syncytial
- syncytial virus
- virus
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title claims abstract description 128
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 78
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 102
- 241000700605 Viruses Species 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 44
- 238000001914 filtration Methods 0.000 claims abstract description 35
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 28
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 claims abstract description 12
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 8
- 230000002779 inactivation Effects 0.000 claims abstract description 8
- 238000011534 incubation Methods 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 238000012216 screening Methods 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 99
- 210000002381 plasma Anatomy 0.000 claims description 85
- 239000000243 solution Substances 0.000 claims description 66
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 54
- 238000001556 precipitation Methods 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 34
- 238000012423 maintenance Methods 0.000 claims description 33
- 238000006386 neutralization reaction Methods 0.000 claims description 32
- 230000003097 anti-respiratory effect Effects 0.000 claims description 28
- 239000000376 reactant Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 238000010790 dilution Methods 0.000 claims description 25
- 239000012895 dilution Substances 0.000 claims description 25
- 238000011085 pressure filtration Methods 0.000 claims description 23
- 238000004448 titration Methods 0.000 claims description 22
- 239000002609 medium Substances 0.000 claims description 21
- 239000006285 cell suspension Substances 0.000 claims description 20
- 238000000502 dialysis Methods 0.000 claims description 19
- 238000000926 separation method Methods 0.000 claims description 18
- 230000003612 virological effect Effects 0.000 claims description 17
- 239000008215 water for injection Substances 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000008351 acetate buffer Substances 0.000 claims description 13
- 230000009849 deactivation Effects 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 238000011068 loading method Methods 0.000 claims description 11
- 239000013642 negative control Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 10
- 239000008363 phosphate buffer Substances 0.000 claims description 10
- 238000010998 test method Methods 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 7
- 239000000539 dimer Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 210000003501 vero cell Anatomy 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000003643 water by type Substances 0.000 claims description 6
- 229920005654 Sephadex Polymers 0.000 claims description 5
- 239000012507 Sephadex™ Substances 0.000 claims description 5
- 238000005571 anion exchange chromatography Methods 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 230000005611 electricity Effects 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002120 nanofilm Substances 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000005723 virus inoculator Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 239000012501 chromatography medium Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000011265 semifinished product Substances 0.000 claims description 3
- 238000005352 clarification Methods 0.000 claims description 2
- 230000012447 hatching Effects 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 239000012898 sample dilution Substances 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 7
- 230000003472 neutralizing effect Effects 0.000 abstract 2
- 238000004440 column chromatography Methods 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 238000005342 ion exchange Methods 0.000 abstract 1
- 238000005374 membrane filtration Methods 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 238000004064 recycling Methods 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 230000007170 pathology Effects 0.000 description 12
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000003750 conditioning effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000010257 thawing Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 208000006379 syphilis Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010035737 Pneumonia viral Diseases 0.000 description 2
- 102000011759 adducin Human genes 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000009421 viral pneumonia Diseases 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
检测项目 | A(普通血浆) | B(高低度特异性血浆) |
蛋白含量 | 56.5g/L | 57.5g/L |
RSV中和抗体效价 | 1:200 | 1:556 |
检测项目 | A(普通血浆) | B(高低度特异性血浆) |
蛋白含量 | 56g/L | 57g/L |
RSV中和抗体效价 | 1:220 | 1:566 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610060348.9A CN105601736B (zh) | 2016-01-28 | 2016-01-28 | 一种抗呼吸道合胞病毒人免疫球蛋白及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610060348.9A CN105601736B (zh) | 2016-01-28 | 2016-01-28 | 一种抗呼吸道合胞病毒人免疫球蛋白及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105601736A true CN105601736A (zh) | 2016-05-25 |
CN105601736B CN105601736B (zh) | 2019-04-23 |
Family
ID=55982142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610060348.9A Active CN105601736B (zh) | 2016-01-28 | 2016-01-28 | 一种抗呼吸道合胞病毒人免疫球蛋白及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105601736B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106928351A (zh) * | 2017-03-28 | 2017-07-07 | 山东泰邦生物制品有限公司 | 一种静注呼吸道合胞病毒人免疫球蛋白及其制备方法 |
CN111234010A (zh) * | 2020-01-20 | 2020-06-05 | 华兰生物工程重庆有限公司 | 降低静注人免疫球蛋白中aca的处理方法 |
WO2020124846A1 (zh) * | 2018-12-18 | 2020-06-25 | 珠海泰诺麦博生物技术有限公司 | 抗呼吸道合胞病毒的中和抗体及其应用 |
CN111499736A (zh) * | 2020-04-28 | 2020-08-07 | 国药集团武汉血液制品有限公司 | 一种静注covid-19人免疫球蛋白的制备方法 |
CN113402604A (zh) * | 2021-07-14 | 2021-09-17 | 北京保图生物技术有限公司 | 快速检测病毒的试剂盒及其制备方法 |
CN113801221A (zh) * | 2020-06-16 | 2021-12-17 | 上海赛伦生物技术股份有限公司 | 一种抗海蛇毒血清纳米膜过滤方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1485342A (zh) * | 2003-07-30 | 2004-03-31 | 广东佰易药业有限公司 | 呼吸道合胞病毒和腺病毒特异性免疫球蛋白制备方法 |
CN101361973A (zh) * | 2008-09-24 | 2009-02-11 | 四川远大蜀阳药业股份有限公司 | 一种治疗水痘的药物及其制备方法 |
CN102178952A (zh) * | 2011-01-28 | 2011-09-14 | 哈尔滨派斯菲科生物制药股份有限公司 | 一种层析法提取破伤风人免疫球蛋白的方法 |
CN103554252A (zh) * | 2013-11-15 | 2014-02-05 | 同路生物制药股份有限公司 | 一种巨细胞人免疫球蛋白及其制备方法 |
US9107906B1 (en) * | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
-
2016
- 2016-01-28 CN CN201610060348.9A patent/CN105601736B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1485342A (zh) * | 2003-07-30 | 2004-03-31 | 广东佰易药业有限公司 | 呼吸道合胞病毒和腺病毒特异性免疫球蛋白制备方法 |
CN101361973A (zh) * | 2008-09-24 | 2009-02-11 | 四川远大蜀阳药业股份有限公司 | 一种治疗水痘的药物及其制备方法 |
CN102178952A (zh) * | 2011-01-28 | 2011-09-14 | 哈尔滨派斯菲科生物制药股份有限公司 | 一种层析法提取破伤风人免疫球蛋白的方法 |
CN103554252A (zh) * | 2013-11-15 | 2014-02-05 | 同路生物制药股份有限公司 | 一种巨细胞人免疫球蛋白及其制备方法 |
US9107906B1 (en) * | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106928351A (zh) * | 2017-03-28 | 2017-07-07 | 山东泰邦生物制品有限公司 | 一种静注呼吸道合胞病毒人免疫球蛋白及其制备方法 |
WO2020124846A1 (zh) * | 2018-12-18 | 2020-06-25 | 珠海泰诺麦博生物技术有限公司 | 抗呼吸道合胞病毒的中和抗体及其应用 |
CN111234010A (zh) * | 2020-01-20 | 2020-06-05 | 华兰生物工程重庆有限公司 | 降低静注人免疫球蛋白中aca的处理方法 |
CN111499736A (zh) * | 2020-04-28 | 2020-08-07 | 国药集团武汉血液制品有限公司 | 一种静注covid-19人免疫球蛋白的制备方法 |
CN111499736B (zh) * | 2020-04-28 | 2021-04-30 | 国药集团武汉血液制品有限公司 | 一种静注covid-19人免疫球蛋白的制备方法 |
CN113801221A (zh) * | 2020-06-16 | 2021-12-17 | 上海赛伦生物技术股份有限公司 | 一种抗海蛇毒血清纳米膜过滤方法 |
CN113402604A (zh) * | 2021-07-14 | 2021-09-17 | 北京保图生物技术有限公司 | 快速检测病毒的试剂盒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105601736B (zh) | 2019-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105601736A (zh) | 一种抗呼吸道合胞病毒人免疫球蛋白及其制备方法 | |
WO2015118149A1 (en) | System, apparatus and method for anti-rsv antibodies and formulations | |
CN107384877A (zh) | 一种慢病毒的纯化方法 | |
CN106540249A (zh) | 一种禽流感(h5n1)或猪繁殖与呼吸综合征(prrs)病毒疫苗的抗原浓缩纯化方法 | |
CN102161702A (zh) | 人血白蛋白的生产方法 | |
CN111471089A (zh) | 一种重组的非洲猪瘟病毒cd2v亚单位蛋白及其制备方法和应用 | |
CN105601735B (zh) | 一种静注巨细胞人免疫球蛋白及其制备方法 | |
CN105396129B (zh) | 一种利用脊髓灰质炎减毒株生产的灭活疫苗 | |
CN105254754A (zh) | 一种静注人免疫球蛋白(ph4)的制备方法 | |
CN105669860B (zh) | 一种抗手足口病人免疫球蛋白及其制备方法 | |
CN113304244A (zh) | 一种用于预防和缓解贫血的血蛋白多肽制备方法 | |
CN103721249B (zh) | 一种流脑疫苗及其制备方法 | |
CN107540743A (zh) | 一种双层析法制备人纤维蛋白原的方法 | |
CN103509100B (zh) | 一种白细胞介素‑1受体拮抗剂突变体 | |
CN112375142B (zh) | 静注新型冠状病毒人免疫球蛋白的制备方法 | |
CN104193822B (zh) | 一种狂犬病人免疫球蛋白制备工艺 | |
CN105399816A (zh) | 一种从转基因山羊乳汁中分离人乳铁蛋白的方法 | |
CN101481692B (zh) | 无血清制备重组人类凝血因子ⅸ | |
CN101024824A (zh) | 一种从生物样品中将登革病毒灭活和去除的方法 | |
CN103554252A (zh) | 一种巨细胞人免疫球蛋白及其制备方法 | |
CN103864926B (zh) | 一种双重病毒灭活制备狂犬人免疫球蛋白的方法 | |
CN101220094A (zh) | 腺病毒anti-Fi、anti-Pb和anti-Hx的免疫球蛋白制备方法 | |
CN101591391B (zh) | 肠道病毒71型人免疫球蛋白及其制备方法 | |
CN111166877A (zh) | 一种狂犬病人免疫球蛋白的制备方法 | |
CN110064052A (zh) | 一种英国梧桐花粉变应原浸提物、其浸液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Ting Inventor after: Yu Yinhang Inventor after: Yang Li Inventor after: Sun Xiaodong Inventor after: Yan Lei Inventor before: Sun Ting Inventor before: Yang Jinping Inventor before: Li Changlu Inventor before: Yu Yinhang Inventor before: Chen Dongming Inventor before: Yang Li Inventor before: Sun Xiaodong Inventor before: Yan Lei |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No.77 Siping Road, Limin Economic Development Zone, Hulan District, Harbin City, Heilongjiang Province Patentee after: Harbin pesfico biopharmaceutical Co.,Ltd. Address before: No.77 Siping Road, Limin Economic Development Zone, Hulan District, Harbin City, Heilongjiang Province Patentee before: HARBIN PAISI FEIKE BIOLOGICAL PHARMACEUTICAL Co.,Ltd. |